Neurogene Inc. (NGNE) has released an update.
Neurogene Inc. announced positive safety results from their Phase 1/2 trial of NGN-401 gene therapy for Rett syndrome, along with the expansion of the trial to Australia, highlighting a strong financial position with a cash runway into the second half of 2026. The company presented data indicating the treatment’s good tolerance in patients, with interim efficacy data expected in the fourth quarter of 2024. This momentum supports Neurogene’s strategic plans to explore gene therapy treatments for additional neurological diseases.
For further insights into NGNE stock, check out TipRanks’ Stock Analysis page.
